Evidence-Based Medicine
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Sep 18, 2018; 9(9): 173-179
Published online Sep 18, 2018. doi: 10.5312/wjo.v9.i9.173
Is there consensus regarding surgical treatment of bone sarcomas?
Thomas Baad-Hansen, Sarah Stammose Freund, Bodil Hammer Bech, Johnny Keller
Thomas Baad-Hansen, Sarah Stammose Freund, Johnny Keller, Department of Orthopaedic Oncology, Aarhus University Hospital, Aarhus C8000, Denmark
Bodil Hammer Bech, Department of Public Health, Aarhus University, Aarhus C8000, Denmark
Author contributions: Baad-Hansen T and Keller J designed the study; Baad-Hansen T, Bech BH performed data analysis; Baad-Hansen T, Keller J, Bech BH and Freund SS wrote the paper.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article, which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Thomas Baad-Hansen, PhD, Chief Doctor, Consultant, Department of Orthopaedic Oncology, Aarhus University Hospital, Nørrebrogade 44, Aarhus C8000, Denmark. baadhansen@dadlnet.dk
Telephone: +45-28603490
Received: April 10, 2018
Peer-review started: April 10, 2018
First decision: May 15, 2018
Revised: May 20, 2018
Accepted: June 27, 2018
Article in press: June 27, 2018
Published online: September 18, 2018
Processing time: 158 Days and 19.6 Hours
Abstract
AIM

To perform an Internet based survey on the surgical management of bone sarcomas in the lower extremity amongst sarcoma surgeons.

METHODS

All orthopedic surgical members of the Scandinavian Sarcoma Group were invited to participate in an online questionnaire. The questionnaire consisted of a clinical case involving resection of a malignant bone tumor. Several questions were asked, subdivided into categories. Among these, surgical/technical considerations, e.g., choice of implant; choice of antibiotics, dosage, and duration of treatment, choice of antithrombotic drug, initial start-up, dosage, and duration were included.

RESULTS

In terms of choice of implant fixation, the majority of surgeons preferred an uncemented prosthesis in younger patients until the age of 50. All participants administer intravenous prophylactic antibiotics for endoprosthetic reconstructive surgery. First choice of antibiotics was cephalosporin. Less common used was glycopeptide, penicillin, or a combination. Duration of prophylactic antibiotics ranged from less than one day to more than four days. All participants used low molecular weight heparins as antithrombotic prophylaxis and 55% of the participants answered that initial treatment was started preoperatively, 3% perioperatively and 42% postoperatively. Duration of the antithrombotic treatment ranged from five days to more than twenty-eight days.

CONCLUSION

The use of resection prosthesis in the treatment of bone sarcomas is a well-established procedure. However, therse is a significant discrepancy in the surgical treatment algorithm between the sarcoma centers. Still the treatment is mainly based on best clinical practice, due to the lack of evidence-based medicine in the surgical management of bone sarcomas.

Keywords: Sarcoma; Reconstruction; Megaprosthesis; Antibiotics; Antithrombotic prophylaxis

Core tip: Today the majority of patients diagnosed with bone sarcomas located in the lower extremities are offered reconstruction with a megaprosthesis. However, no clear golden standard is available in the international surgical oncology community with regard to choice of implant, choice of antibiotics, dosage, and duration of treatment, or choice of antithrombotic drug, initial start-up, dosage, and duration. The current study reveals a clear lack of consensus.